Motesanib

DB05575InvestigationalSmall molecule

Investigated for use/treatment in solid tumors.

Mechanism: Pharmacologically active on Mast/stem cell growth factor receptor Kit, Proto-oncogene tyrosine-protein kinase receptor Ret, and Vascular endothelial growth factor receptor
Curator reviewed
Primary indication: Investigated for use/treatment in solid tumors.Curator reviewed
Formula / weight: C₂₂H₂₃N₅O · 373.4509 g/mol (avg)
Code names: AMG-706

Resolves to

Compound

UNIIU1JK633AYICAS453562-69-1ChEMBLCHEMBL572881ChEBI51098

Clinical / RWD

PharmGKBPA166118340

Structure

InChIKeyRAHBGWKEPAQNFF-UHFFFAOYSA-NSMILESCC1(C)CNC2=CC(NC(=O)C3=C(NCC4=CC=NC=C4)N=CC=C3)=CC=C12

Targets

P10721KITP07949RETP35968KDR

What you can answer from here — as of September 19, 2026

4Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

27Drug interactionsStructured to mechanism, not free text

20Clinical trialsPhase, status and sponsor resolved per trial

13+ReferencesStructured and connected to the statements they support

Which drugs share a target with Motesanib, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Log In Paid Account Log In